ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08727
0,05%
Bitcoin
66.926,12
2,59%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lipella Pharmaceuticals Inc (LIPO)

  7. Lipella Pharmaceuticals Inc (LIPO) News

LIPO

Lipella Pharmaceuticals (LIPO)

Lipella Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LIPO
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIPOLipella Pharmaceuticals Inc
09/05/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
06/05/202422h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
17/04/202414h00GlobeNewswire Inc.Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseNASDAQ:LIPOLipella Pharmaceuticals Inc
05/04/202414h00GlobeNewswire Inc.Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024NASDAQ:LIPOLipella Pharmaceuticals Inc
03/04/202414h00GlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisNASDAQ:LIPOLipella Pharmaceuticals Inc
07/03/202421h23GlobeNewswire Inc.PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
06/03/202423h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
06/03/202423h03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
05/03/202414h00GlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical PipelineNASDAQ:LIPOLipella Pharmaceuticals Inc
27/02/202423h04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
27/02/202422h51Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LIPOLipella Pharmaceuticals Inc
20/02/202414h00GlobeNewswire Inc.Lipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceNASDAQ:LIPOLipella Pharmaceuticals Inc
09/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
07/02/202423h29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
01/02/202422h09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIPOLipella Pharmaceuticals Inc
25/01/202422h06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
03/01/202422h59Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIPOLipella Pharmaceuticals Inc
20/12/202314h00GlobeNewswire Inc.Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedNASDAQ:LIPOLipella Pharmaceuticals Inc
28/11/202323h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
22/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
14/11/202312h22Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
14/11/202312h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
10/11/202314h00PR Newswire (US)FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
09/11/202322h07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
09/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
07/11/202323h22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LIPOLipella Pharmaceuticals Inc
01/11/202321h06Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LIPOLipella Pharmaceuticals Inc
25/10/202322h05PR Newswire (US)Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:LIPOLipella Pharmaceuticals Inc
24/10/202314h00PR Newswire (US)Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:LIPOLipella Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LIPO

Kürzlich von Ihnen besucht

NASDAQ
SWSSW
Clean Energy Special Sit...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten